MTAA
DIA
Market cap4.69bUSD
Sep 17, Last price
76.26EUR
1D
1.30%
1Q
17.21%
Jan 2017
35.57%
IPO
537.63%
Name
DiaSorin SpA
Chart & performance
P/E
26.22
P/S
3.41
EPS
2.91
Div yield, %
1.57%
Shrs. gr., 5y
0.31%
Rev. gr., 5y
6.28%
Revenues
1.20b
+0.84%
Net income
156m
-17.27%
CFO
343m
-4.47%
Dividend
May 18, 20261.3 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Related entities
Parent
FINDE S.P.A.
Subsidiaries (2)
DIASORIN INC.
DIASORIN ITALIA S.P.A.
Key people
John Gerace
President, DiaSorin Molecular LLC · since 2019
Ugo Gay
Senior Corporate Vice President - Industrial Operations · since 2019
Riccardo Fava
Corporate Vice President Communication and Investor Relations · since 2019
Headquarters & legal address
VIA CRESCENTINO, SNC
SALUGGIA, VC 13040
IT
SALUGGIA, VC 13040
IT
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||